

Application No. 09/743,781
Paper Dated January 27, 2004
Reply to USPTO Correspondence of October 27, 2003
Attorney Docket No. 4303-030806

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (currently amended): A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease or related disorders, comprising regulating a soluble A β antagonizing the phospholipase A2/arachidonic acid/5-lipoxygenase/cyclooxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of a phospholipase A2 inhibitor to the individual.
2. (previously presented): The method according to claim 1, further defined as upregulating the soluble A β pro-inflammatory pathway.
3. (previously presented): The method according to claim 1, further defined as down-regulating the soluble A β pro-inflammatory pathway.

4-21. (canceled)